EBC-46 (tigilanol tiglate) pivotal trials in the USA and EU show significant progress
October, 2017 Update
Animal health development of tigilanol tiglate is progressing well.
In the USA we have the FDA Centre for Veterinary Medicines Mast Cell Tumour Pivotal Field Efficacy study which is in the final stages of recruitment for the 120 dogs required. The trial is expected to be finished by late Q1 2018.
The UK and EU canine clinical trial programme is focused on the Soft Tissue Sarcoma Pivotal Field Efficacy study which is also progressing well with a targeted completion date by late Q2 2018
The completion of both clinical trials are critical and pivotal steps as we finalise the regulatory packages for canine oncology indications in the USA and EU.